ALDOA Expression in Bladder Urothelial Carcinoma
Immunohistochemical Expression and Prognostic Significance of ALDOA in Bladder Urothelial Carcinoma.
1 other identifier
observational
50
0 countries
N/A
Brief Summary
- 1.Study the immunohistochemical expression of ALDOA in bladder urothelial cancer.
- 2.Correlate between ALDOA expression in specimens and different cilnicopathological factors.
- 3.Correlate between ALDOA expression and urothelial cancer prognosis and survival.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2024
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 9, 2024
CompletedFirst Posted
Study publicly available on registry
August 13, 2024
CompletedStudy Start
First participant enrolled
September 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2025
CompletedAugust 13, 2024
August 1, 2024
10 months
August 9, 2024
August 9, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Evaluate the immunohistochemical expression of ALDOA in bladder urothelial carcinoma.
Microscopic examination of bladder urothelial carcinoma spicemens and staining them with ALDOA marker
Baseline
Secondary Outcomes (1)
Evaluate relation between ALDOA expression and cilnicopathological features and patient survival.
Baseline
Interventions
Immunohistochemical expression of ALDOA in bladder urothelial carcinoma
Eligibility Criteria
The study will be conducted using formalin fixed paraffin embedded blocks of fifty cases of urothelial carcinomas . These blocks will be obtained from laboratory archives of the Pathology Department, Assiut University Hospital, Faculty of Medicine. Clinical data for this study will be obtained from laboratory archives of the pathology department, Assiut University Hospital, Assiut University.
You may qualify if:
- All cases diagnosed as bladder urothelial cancer with known follow-up data and presence of muscle proper detected in the specimens.
You may not qualify if:
- Subtypes of bladder cancer other than urothelial carcinoma subtype.
- Cases of urothelial carcinoma without known follow up data.
- Cases of urothelial carcinoma without muscle proper detected in the specimen.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Links
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Dalia Elsers, Professor
Head of Pathology Department
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Demonstrator
Study Record Dates
First Submitted
August 9, 2024
First Posted
August 13, 2024
Study Start
September 1, 2024
Primary Completion
July 1, 2025
Study Completion
August 1, 2025
Last Updated
August 13, 2024
Record last verified: 2024-08